Jiuzhou Pharma/九洲药业

Jiuzhou Pharma is a global Contract Development and Manufacturing Organization (CDMO) focused on the development and manufacturing of small molecule and peptide APIs (active pharmaceutical ingredients) and finished dose drug products With subsidiaries in China, North America,, Europe, Singapore, and Japan, with a company history over 50 years. Jiuzhou Pharma provides full-lifecycle contract development and manufacturing services from fully compliant cGMP laboratories to research institutions and biotech and pharmaceutical companies worldwide and has globally launched 34 innovative drugs. One-stop CDMO services span preclinical research, process R&D for Active Pharmaceutical Ingredients (APIs), Drug Products, small molecules, peptides, and drug conjugates supporting all clinical phases through commercial production. With an EcoVadis Gold rating, Jiuzhou Pharma continues to push the boundaries of sustainable pharmaceutical manufacturing. A commitment to continuous innovation in green chemistry, lifecycle impact reduction, and responsible global manufacturing ensures that we remain a trusted, forward-thinking CDMO partner for the future of pharmaceuticals. Production Facilities Taizhou and Hangzhou in Zhejiang Province and Yancheng and Suzhou in Jiangsu Province Zhongshan in Guangdong Province R & D centers Hangzhou, Taizhou, Nanjing in China Brevard, North Carolina USA Kanagawa, Japan Konstanz, Germany Stock symbol 603456.SH Specialties: small molecules, peptides, drug conjugates, formulation, tag-assisted LPPS, flow chemistry